Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Studymetrix Research LLC

Neither a doctor nor a teaching hospital

Research payments

$19,092,519

624 payments

Through program year 2025, Studymetrix Research LLC is reported as receiving $19,092,519 in research payments, across 624 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $4,098,201 71
2024 Research $3,975,309 79
2023 Research $3,883,409 105
2022 Research $2,631,372 89
2021 Research $2,383,707 119
2020 Research $1,370,167 73
2019 Research $750,353 88

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $15,602,237 251 payments
  2. Pfizer Inc. $1,562,059 60 payments
  3. Allergan Inc. $450,388 90 payments
  4. Biohaven Pharmaceuticals, Inc. $278,306 54 payments
  5. Novo Nordisk AS $263,726 47 payments
  6. H. Lundbeck A S $248,502 27 payments
  7. Vertex Pharmaceuticals Incorporated $216,118 3 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $152,604 36 payments
  9. AbbVie, Inc. $138,568 41 payments
  10. Novartis Pharmaceuticals Corporation $110,698 5 payments
Studies the money was for Research payments · program years 2019–2025
  1. Efficacy and Safety of Tirzepatide Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight- Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-1) $1,251,081 9 payments
  2. A Phase 2 Randomized Doubleblind Placebo Controlled Dose Ranging Dose Finding Parallel Group Study to Assess Efficacy and Safety of Pf07081532 and Open Label Oral Semaglutide in Adults With Type 2 Diabetes Mellitus T2dm Inadequately Controlled on Metformin and Separately Pf07081532 Compared to Matching Placebo in Adults With Obesity But Without T2dm $1,077,719 30 payments
  3. A Master Protocol to Investigate the Efficacy and Safety of Ly3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity Or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (Triumph-1) $902,931 4 payments
  4. Randomized, Placebo Controlled, Phase 2 Clinical Trial to Evaluate Ly3556050 for the Treatment of Osteoarthritis Pain $850,875 9 payments
  5. A Phase 2 Study of Once-Weekly Ly3437943 Compared With Placebo in Participants Who Have Obesity Or Are Overweight With Weight-Related Comorbidities $762,983 4 payments
  6. A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity Or Overweight With Weight-Related Comorbidities (Attain-Maintain) $562,597 4 payments
  7. A Study of Retatrutide (Ly3437943) in Participants Who Have Obesity Or Overweight (Triumph-1) $561,995 2 payments
  8. Phase 2 Study With Combination of Vemurafenib With Cobimetinib in B-Raf V600e/K Mutated Melanoma Patients to Normalize LDH and Optimize Nivolumab and Ipilimumab Therapy $557,376 4 payments
  9. Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo for Maintenance of Weight Loss in Participants Without Type 2 Diabetes Who Have Obesity Or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (Surmount-4) $556,678 5 payments
  10. A Phase 3B, Randomized Controlled Study to Evaluate the Efficacy and Safety of Tirzepatide Compared to Semaglutide 2.4 MG in Adults Who Have Obesity Or Overweight With Weight-Related Comorbidities (Surmount-5) $480,200 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record